In recent years, there has been a growing trend in the global pharmaceutical industry
to develop highly potent molecules (HPAPI): the global API market confirms a steady growth
of 5.1% from 2007 to 2020, with an annual increase of 8.7% expected from 2022 to 2027.
This increasingly draws attention, in addition to GMP quality requirements,
also to regulations regarding worker safety and environmental protection.
This is why Techniconsult has chosen to integrate into the corporate organization a new Business Unit dedicated to Containment Test & Monitoring activities for verifying the containment performance of active pharmaceutical ingredient, intermediate, and formulation production, finished drugs to ensure the safety and protection of personnel, products (cross-contamination), and the environment.
The team of the new department is led by Michele Grassi with over fifteen years of experience in the field of industrial hygiene, environmental monitoring, and containment assessment in chemical and pharmaceutical companies.
Thanks to his experience, during which he has acquired good knowledge of different types of processes, containment solutions, and process equipment, he is now able to offer targeted solutions for every type of process.
The synergy of the Techniconsult Group allows us to offer not only testing and monitoring activities in the field but also consulting activities, such as the development of a Risk Assessment and consequently the possibility of implementing the identified solutions.
To learn more, visit Containment & Monitoring.
Articoli correlati
May 7, 2023
AQE Srl a new company dedicated to automation
In order to continue expanding and developing our expertise, a new entity was…
December 14, 2022
PQE Group
and Techniconsult Group
Quality consulting multinational PQE Group, and engineering company…
November 29, 2022
New Biotech Center of Excellence
Today, the Chiesi Pharmaceutical Group celebrated in Parma the “Start of Work”…